Expression and clinical value of CD105 in renal cell carcinoma based on data mining in The Cancer Genome Atlas

Shi,Donghui; Che,Jianping; Yan,Yang; Peng,Bo; Yao,Xudong; Guo,Changcheng

doi:10.3892/etm.2019.7493

Expression and clinical value of CD105 in renal cell carcinoma based on data mining in The Cancer Genome Atlas

Authors:
- Donghui Shi
- Jianping Che
- Yang Yan
- Bo Peng
- Xudong Yao
- Changcheng Guo
View Affiliations

Affiliations: Department of Urology, Shanghai 10th People's Hospital, Tongji University, Shanghai 200072, P.R. China
Published online on: April 17, 2019 https://doi.org/10.3892/etm.2019.7493
Pages: 4499-4505
Copyright: © Shi et al. This is an open access article distributed under the terms of Creative Commons Attribution License.

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

The objective of the present study was to assess the expression of CD105 and its association with overall survival in three subtypes of renal cell carcinoma (RCC), namely clear cell (cc)RCC, papillary (p)RCC and chromophobe (ch)RCC. Data regarding the transcriptome and copy number of genes in RCC tumor samples and survival were obtained from The Cancer Genome Atlas. Bioinformatics analysis revealed that CD105 is overexpressed in ccRCC tumor tissue vs. normal renal tissue, and a higher CD105 copy number in ccRCC tissues was significantly associated with longer patient survival. The effect of the mRNA expression of CD105 in all three types of RCC and the copy number in pRCC and chRCC on patient survival was insignificant, but certain trends were observed. In addition, CD105 mRNA expression was associated with the metastasis and tumor stage, as well as pathological stage in ccRCC and pRCC. Pathway enrichment analysis revealed that CD105 may, through translation initiation of associated genes, promote RCC progression. The results of the present study suggest that in RCC tumors, the association of CD105 with different stages is complex. To evaluate the role of CD105 in RCC, its function should be assessed in addition to its expression. The exact influence of CD105 mRNA expression and copy number in RCC tumors on patient survival and the underlying mechanisms require further elucidation.

View Figures

View References

1	Rini BI, Campbell SC and Escudier B: Renal cell carcinoma. Lancet. 373:1119–1132. 2009. View Article : Google Scholar : PubMed/NCBI
2	Siegel RL, Miller KD and Jemal A: Cancer statistics, 2017. CA Cancer J Clin. 67:7–30. 2017. View Article : Google Scholar : PubMed/NCBI
3	King SC, Pollack LA, Li J, King JB and Master VA: Continued increase in incidence of renal cell carcinoma, especially in young patients and high grade disease: United States 2001 to 2010. J Urol. 191:1665–1670. 2014. View Article : Google Scholar : PubMed/NCBI
4	Linehan WM and Ricketts CJ: Decade in review-kidney cancer: Discoveries, therapies and opportunities. Nat Rev Urol. 11:614–616. 2014. View Article : Google Scholar : PubMed/NCBI
5	Bedke J, Gauler T, Grünwald V, Hegele A, Herrmann E, Hinz S, Janssen J, Schmitz S, Schostak M, Tesch H, et al: Systemic therapy in metastatic renal cell carcinoma. World J Urol. 35:179–188. 2017. View Article : Google Scholar : PubMed/NCBI
6	Brown C: Targeted therapy: An elusive cancer target. Nature. 537 (Suppl):S106–S108. 2016. View Article : Google Scholar : PubMed/NCBI
7	Yang F, Wu Q, Zhang Y, Xiong H, Li X, Li B, Xie W, Zhang L, Xu M, Zhang K and He F: LncRNA LOC653786 promotes growth of RCC cells via upregulating FOXM1. Oncotarget. 9:12101–12111. 2018. View Article : Google Scholar : PubMed/NCBI
8	Choueiri TK and Motzer RJ: Systemic therapy for metastatic renal-cell carcinoma. N Engl J Med. 376:354–366. 2017. View Article : Google Scholar : PubMed/NCBI
9	Al-Hajj M and Clarke MF: Self-renewal and solid tumor stem cells. Oncogene. 23:7274–7282. 2004. View Article : Google Scholar : PubMed/NCBI
10	Corrò C and Moch H: Biomarker discovery for renal cancer stem cells. J Pathol Clin Res. 4:3–18. 2018. View Article : Google Scholar : PubMed/NCBI
11	Liu L, Wang Q, Mao J, Qin T, Sun Y, Yang J, Han Y, Li L and Li Q: Salinomycin suppresses cancer cell stemness and attenuates TGF-β-induced epithelial-mesenchymal transition of renal cell carcinoma cells. Chem Biol Interact. 296:145–153. 2018. View Article : Google Scholar : PubMed/NCBI
12	Matak D, Brodaczewska KK, Szczylik C, Koch I, Myszczyszyn A, Lipiec M, Lewicki S, Szymanski L, Zdanowski R and Czarnecka AM: Functional significance of CD105-positive cells in papillary renal cell carcinoma. BMC Cancer. 17:212017. View Article : Google Scholar : PubMed/NCBI
13	Saeednejad Zanjani L, Madjd Z, Abolhasani M, Shariftabrizi A, Rasti A and Asgari M: Expression of CD105 cancer stem cell marker in three subtypes of renal cell carcinoma. Cancer Biomark. 21:821–837. 2018. View Article : Google Scholar : PubMed/NCBI
14	Duff SE, Li C, Garland JM and Kumar S: CD105 is important for angiogenesis: Evidence and potential applications. FASEB J. 17:984–992. 2003. View Article : Google Scholar : PubMed/NCBI
15	Dallas NA, Samuel S, Xia L, Fan F, Gray MJ, Lim SJ and Ellis LM: Endoglin (CD105): A marker of tumor vasculature and potential target for therapy. Clin Cancer Res. 14:1931–1937. 2008. View Article : Google Scholar : PubMed/NCBI
16	Bussolati B, Bruno S, Grange C, Ferrando U and Camussi G: Identification of a tumor-initiating stem cell population in human renal carcinomas. FASEB J. 22:3696–3705. 2008. View Article : Google Scholar : PubMed/NCBI
17	Hasmim M, Bruno S, Azzi S, Gallerne C, Michel JG, Chiabotto G, Lecoz V, Romei C, Spaggiari GM, Pezzolo A, et al: Isolation and characterization of renal cancer stem cells from patient-derived xenografts. Oncotarget. 7:15507–15524. 2016. View Article : Google Scholar : PubMed/NCBI
18	Song L, Ye W, Cui Y, Lu J, Zhang Y, Ding N, Hu W, Pei H, Yue Z and Zhou G: Ecto-5′-nucleotidase (CD73) is a biomarker for clear cell renal carcinoma stem-like cells. Oncotarget. 8:31977–31992. 2017.PubMed/NCBI
19	Feldman DR and Motzer RJ: Novel targets and therapies for metastatic renal cell carcinoma. Oncology (Williston Park). 20:1745–1756. 2006.PubMed/NCBI
20	Yang X, Zhang D, Chong T, Li Y, Wang Z and Zhang P: Expression of CK19, CD105 and CD146 are associated with early metastasis in patients with renal cell carcinoma. Oncol Lett. 15:4229–4234. 2018.PubMed/NCBI
21	Yagasaki H, Kawata N, Takimoto Y and Nemoto N: Histopathological analysis of angiogenic factors in renal cell carcinoma. Int J Urol. 10:220–227. 2003. View Article : Google Scholar : PubMed/NCBI
22	Saroufim A, Messai Y, Hasmim M, Rioux N, Iacovelli R, Verhoest G, Bensalah K, Patard JJ, Albiges L, Azzarone B, et al: Tumoral CD105 is a novel independent prognostic marker for prognosis in clear-cell renal cell carcinoma. Br J Cancer. 110:1778–1784. 2014. View Article : Google Scholar : PubMed/NCBI
23	Myszczyszyn A, Czarnecka AM, Matak D, Szymanski L, Lian F, Kornakiewicz A, Bartnik E, Kukwa W, Kieda C and Szczylik C: The role of hypoxia and cancer stem cells in renal cell carcinoma pathogenesis. Stem Cell Rev. 11:919–943. 2015. View Article : Google Scholar : PubMed/NCBI
24	Hu J, Guan W, Liu P, Dai J, Tang K, Xiao H, Qian Y, Sharrow AC, Ye Z, Wu L and Xu H: Endoglin is essential for the maintenance of self-renewal and chemoresistance in renal cancer stem cells. Stem Cell Reports. 9:464–477. 2017. View Article : Google Scholar : PubMed/NCBI
25	Seon BK, Matsuno F, Haruta Y, Kondo M and Barcos M: Long-lasting complete inhibition of human solid tumors in SCID mice by targeting endothelial cells of tumor vasculature with antihuman endoglin immunotoxin. Clin Cancer Res. 3:1031–1044. 1997.PubMed/NCBI